| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 2,337 | 2,665 | 2,960 | 3,416 | 3,792 | 4,208 | 4,391 | 4,997 | 5,503 | 6,097 | 6,685 | 7,005 |
| Expenses | 1,977 | 2,250 | 2,505 | 2,774 | 3,074 | 3,337 | 3,389 | 3,832 | 4,143 | 4,396 | 4,715 | 4,902 |
| EBITDA | 360 | 415 | 455 | 642 | 718 | 871 | 1,002 | 1,165 | 1,360 | 1,701 | 1,970 | 2,103 |
| Operating Profit % | 13 % | 14 % | 14 % | 16 % | 16 % | 18 % | 21 % | 22 % | 23 % | 25 % | 26 % | 27 % |
| Depreciation | 15 | 14 | 16 | 16 | 17 | 60 | 58 | 66 | 70 | 71 | 72 | 74 |
| Interest | 1 | 3 | 2 | 4 | 2 | 9 | 18 | 19 | 16 | 12 | 11 | 20 |
| Profit Before Tax | 344 | 398 | 437 | 622 | 699 | 803 | 926 | 1,080 | 1,274 | 1,618 | 1,887 | 2,009 |
| Tax | 115 | 143 | 160 | 220 | 249 | 210 | 235 | 281 | 324 | 417 | 473 | 497 |
| Net Profit | 229 | 255 | 277 | 401 | 450 | 593 | 691 | 799 | 949 | 1,201 | 1,414 | 1,509 |
| EPS in ₹ | 107.75 | 120.12 | 130.19 | 188.81 | 211.93 | 279.04 | 325.04 | 375.87 | 446.80 | 565.28 | 665.62 | 710.10 |
Abbott
Abbott
28,905.00
0.00
(0.00%)
Market Cap
₹61,421.11 Cr
PE Ratio
40.66
Volume
20,873.00
Day High - Low
₹28,975.00 - ₹28,290.00
52W High-Low
₹37,000.00 - ₹25,325.00
Key Fundamentals
Market Cap
61,421.11 Cr
EPS
665.62
PB Ratio
15.30
Book Value
1,887.49
EBITDA
1,970.20
Dividend Yield
1.65 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
33.41
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from6 analysts
Actual
Company News
View All News
Abbott India announces resignation of Director Ambati Venu effective December 31, 2025, and appointment of Vivek Mohan as Additional Non-Executive Director from January 1, 2026.
Abbott India announced that Mr. Rajan Kalantre, Director of Business Human Resources, will move to another Abbott affiliate effective December 16, 2025, with his role ending December 15, 2025. The company appointed Ms. Vinutha Mufti as the new Director of Business Human Resources effective December 16, 2025, bringing over two decades of HR experience including progressive roles at Abbott since 2015 and previous experience at IBM.
The government has approved Kartik Rajendran's appointment as the new Managing Director of Abbott India. This leadership change affects the pharmaceutical company's management structure and operations going forward.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,717.20 | #1 4,12,013.80 | 39.34 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 38.06 | |
6,390.50 | 1,69,647.70 | 68.62 | 9,712.00 | 18.67 | 2,191 | 35.10 | 47.03 | |
3,793.70 | 1,28,396.05 | 60.30 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.78 | |
1,494.00 | 1,20,678.46 | 22.37 | 28,409.50 | 7.12 | 5,291 | 3.71 | 43.28 | |
1,268.60 | 1,05,879.10 | 18.46 | 33,741.20 | 16.73 | 5,725 | -0.38 | 51.53 | |
2,082.10 | 95,100.86 | 22.20 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 50.57 | |
904.60 | 91,023.93 | #1 18.24 | 23,511.00 | 18.55 | 4,615 | 34.60 | 35.42 | |
2,182.00 | 90,063.90 | 51.01 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 45.35 | |
1,200.10 | 69,702.00 | 20.47 | 32,345.60 | 9.43 | 3,484 | 3.81 | 51.00 | |
5,505.00 | 65,820.53 | 27.46 | 13,458.30 | 3.70 | 2,216 | 10.98 | 40.09 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
9.64 %
Net Income Growth
17.75 %
Cash Flow Change
-16.57 %
ROE
2.86 %
ROCE
-0.57 %
EBITDA Margin (Avg.)
5.63 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 | 5,917 |
| Fixed Assets | 96 | 109 | 110 | 81 | 105 | 270 | 251 | 271 | 237 | 225 | 336 |
| Current Assets | 1,226 | 1,451 | 1,893 | 2,266 | 2,761 | 3,205 | 3,487 | 3,853 | 3,025 | 3,246 | 4,742 |
| Capital Work in Progress | 4 | 3 | 6 | 2 | 1 | 2 | 1 | 1 | 4 | 10 | 18 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,274 | 1,505 | 1,950 | 2,333 | 2,835 | 3,275 | 3,589 | 3,953 | 4,315 | 4,958 | 5,563 |
| Total Liabilities | 1,374 | 1,617 | 2,066 | 2,416 | 2,941 | 3,547 | 3,840 | 4,224 | 4,556 | 5,194 | 5,917 |
| Current Liabilities | 397 | 382 | 632 | 668 | 857 | 891 | 1,031 | 1,203 | 1,206 | 1,343 | 1,407 |
| Non Current Liabilities | 39 | 39 | 47 | 55 | 75 | 224 | 207 | 201 | 161 | 152 | 277 |
| Total Equity | 938 | 1,196 | 1,387 | 1,693 | 2,009 | 2,432 | 2,602 | 2,820 | 3,189 | 3,699 | 4,233 |
| Reserve & Surplus | 916 | 1,174 | 1,366 | 1,672 | 1,987 | 2,410 | 2,581 | 2,799 | 3,167 | 3,678 | 4,212 |
| Share Capital | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -30 | 91 | 62 | -165 | 99 | 8 | 73 | -86 | 107 | 52 | 269 |
| Investing Activities | -187 | -77 | -155 | -215 | -257 | -401 | -72 | -396 | -148 | -416 | 182 |
| Operating Activities | 215 | 249 | 307 | 153 | 499 | 626 | 727 | 948 | 893 | 1,213 | 1,012 |
| Financing Activities | -58 | -80 | -90 | -102 | -143 | -217 | -582 | -637 | -639 | -745 | -925 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.18 % | 0.18 % | 0.18 % | 0.16 % | 0.16 % | 0.16 % | 0.16 % | 0.16 % |
| DIIs | 4.60 % | 5.80 % | 4.30 % | 4.20 % | 4.96 % | 5.24 % | 7.73 % | 8.39 % | 8.62 % | 8.67 % | 8.71 % | 8.74 % | 8.91 % | 8.81 % | 8.99 % | 9.01 % | 8.92 % | 9.19 % | 9.11 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 15.83 % | 15.60 % | 15.81 % | 15.15 % | 14.72 % | 14.60 % | 14.25 % | 14.07 % | 13.95 % | 13.89 % | 13.97 % | 13.80 % | 13.86 % | 13.65 % | 13.59 % | 13.66 % | 13.35 % | 13.43 % |
| Others | 4.26 % | 3.38 % | 5.11 % | 5.01 % | 4.91 % | 5.06 % | 2.68 % | 2.37 % | 2.32 % | 2.39 % | 2.42 % | 2.13 % | 2.12 % | 2.16 % | 2.21 % | 2.25 % | 2.28 % | 2.31 % | 2.31 % |
| No of Share Holders | 0 | 84,478 | 75,540 | 73,417 | 83,236 | 90,567 | 82,113 | 83,526 | 72,086 | 69,582 | 68,885 | 72,252 | 69,382 | 71,588 | 69,449 | 67,892 | 69,934 | 67,584 | 71,199 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 40 | 55 | 65 | 250 | 275 | 275 | 325 | 410 | 475 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.75 | 0.42 | 1.67 | 1.55 | 1.26 | 1.2 | 1.33 | 1.64 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Jul 2021 |  Dividend | ₹ 155.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
| 21 Jul 2021 | Dividend | ₹ 120.00 /share | 19 Jul 2021 | 16,224.75 | 17,427.95 |
| 04 Aug 2022 | Dividend | ₹ 130.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 04 Aug 2022 | Dividend | ₹ 145.00 /share | 02 Aug 2022 | 16,529.20 | 20,621.45 |
| 21 Jul 2023 | Dividend | ₹ 145.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 21 Jul 2023 | Dividend | ₹ 180.00 /share | 21 Jul 2023 | 20,970.55 | 23,665.10 |
| 19 Jul 2024 | Dividend | ₹ 410.00 /share | 19 Jul 2024 | 25,945.60 | 28,795.65 |
| 08 Aug 2024 |  Annual General Meeting | NA | 08 Aug 2024 | 25,945.60 | 28,136.85 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 28,526.15 | 29,115.20 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 26,518.15 | 26,142.55 |
| 15 May 2025 | Quarterly Result Announcement | NA | 15 May 2025 | 30,145.75 | 30,348.45 |
| 25 Jul 2025 | Dividend | ₹ 475.00 /share | 25 Jul 2025 | 30,348.45 | 34,580.00 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 33,595.00 | 32,980.00 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 30,348.45 | 32,342.10 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 29,770.00 | 29,366.35 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Directorate
4 days ago
4 days agoClosure of Trading Window10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Change in ManagementNov 25, 2025
Nov 25, 2025Approval Of Central Government For Appointment Of Managing DirectorNov 24, 2025
Nov 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Nov 07, 2025Unaudited Financial Results For The Quarter Ended September 30 2025.Nov 06, 2025
Nov 06, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Nov 06, 2025Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Oct 29, 2025
Oct 29, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportOct 15, 2025
Oct 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 08, 2025
Oct 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Sep 24, 2025Closure of Trading WindowSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 12, 2025
Sep 12, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotSep 11, 2025
Sep 11, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 04, 2025
Aug 04, 2025Disclosure Under Regulation 30Aug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 29, 2025
Jul 29, 2025Communication Providing The Weblink Including Path Of Annual Report.Jul 18, 2025
Jul 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 18, 2025
Jul 18, 2025Notice Of The 81St Annual General Meeting Of The Company.Jul 18, 2025
Jul 18, 2025Reg. 34 (1) Annual Report.Jul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Communication To Shareholders : Intimation About Tax Deduction At Source On Dividend.Jun 18, 2025
Jun 18, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Record Date For Entitlement Of DividendMay 15, 2025
May 15, 2025Annual General Meeting On August 13 2025May 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 15, 2025
May 15, 2025Results For The Financial Year Ended March 31 2025May 15, 2025
May 15, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 07, 2025
May 07, 2025Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.May 07, 2025
May 07, 2025Announcement Under Regulation 30.Apr 30, 2025
Apr 30, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Mar 26, 2025Mutual Fund Holdings
Bandhan Large & Mid Cap Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
Edelweiss Business Cycle Fund Direct-Growth 
360 ONE Quant Fund Direct - Growth 
LIC MF Multi Cap Fund Direct - Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
SBI Quant Fund Direct-Growth 
Axis Midcap Direct Plan-Growth 
UTI Multi Asset Allocation Fund Direct-Growth 
Bank of India Multi Cap Fund Direct-Growth 
ITI Mid Cap Fund Direct - Growth 
Groww Value Fund Direct-Growth 
Motilal Oswal Nifty Midcap 150 Index Fund Direct - Growth 
NJ ELSS Tax Saver Scheme Direct - Growth Technical Indicators
RSI(14)
Neutral 54.00
ATR(14)
Volatile 552.42
STOCH(9,6)
Neutral 67.28
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 100.77
ADX(14)
Strong Trend 33.01
UO(9)
Bearish 58.23
ROC(12)
Uptrend And Accelerating 2.96
WillR(14)
Overbought -5.45
About Abbott
Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Website
Chairperson NameMunir Shaikh
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
